SHANGHAI - China's National Development and Reform Commission issued Oct. 2 a guideline price for its Essential Drug List, which stipulates price ceilings for 296 drugs on the first part of the list
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
Fresh from having sold Anthos to Novartis, the new CEO is expected to update the oncology and dermatology-focused firm's strategy.
Green light follows a recent rejection by the US FDA to partner Regeneron's request for an extension to the dosing interval.
Recent moves in the industry include C-suite changes at Atalanta Therapeutics and Climb Bio, plus seven companies get new CMOs.
